February 28 – March 1, 2017 | San Francisco





Content Hub

  • pp-thumbnail

    Past Presentations Pack

    1. Cardiac Myosin Activation for the Treatment of Heart Failure

    Fady Malik, Executive VP, Research & Development, Cytokinetics

    2. The Latest Thinking on Regenerative Approaches to CVD and Heart Failure

    Thomas Povsic, Associate Professor of medicine, Interventional Cardiologist, Duke Clinical Research Institute (DCRI)

    3. Regulatory Considerations: What the Regulatory Authorities Want to See at Each Stage of Development

    Jeff Riesmeyer, Senior Medical Director, Cardiovascular, Eli Lilly and Company

  • content-thumbnail

    Induced pluripotent stem cells: at the heart of cardiovascular precision medicine

    Ian Y. Chen, Elena Matsa, and Joseph C. Wu

    In this review, and in the light of the Precision Medicine Initiative, Dr. Wu evaluates the role of human induced pluripotent stem cell (hiPSC) technology in the advancement of cardiovascular research and medicine.

    By enabling the derivation of cells with patient-specific phenotypes, hiPSC technology is set to be a crucial approach to the future of cardiovascular precision medicine, with promising progress being made in this field to harness this technology for cardiovascular disease modeling and drug development.